Evidence map›Paper›PMID 36830994›Full record

ArticleBiomedicines2023

Brain-Type Creatine Kinase Release from Cultured Osteoclasts Exposed to Neridronate in Children Affected by Osteogenesis Imperfecta Type 1.

Maria Felicia Faienza, Albina Tummolo, Mauro Celli, Roberto Finocchiaro, Laura Piacente, Francesca Di Serio, Grazia Paola Nicchia, Giacomina Brunetti, Patrizia D'Eufemia

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Maria Felicia FaienzaDepartment of Precision and Regenerative Medicine and Ionian area, University of Bari, "A. Moro", 70124 Bari, Italy.ORCID 0000-0002-1899-8337
Albina TummoloDepartment of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 Bari, Italy.ORCID 0000-0001-8823-8061
Mauro CelliDepartment of Pediatric, Sapienza University of Rome, 00185 Rome, Italy.
Roberto FinocchiaroDepartment of Pediatric, Sapienza University of Rome, 00185 Rome, Italy.
Laura PiacenteGiovanni XXIII Pediatric Hospital, 70126 Bari, Italy.
Francesca Di SerioClinical Pathology Unit, Azienda Ospedaliero-Universitaria (AOU) Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, 70124 Bari, Italy.
Grazia Paola NicchiaDepartment of Biosciences, Biotechnologies and Environment, University of Bari "A. Moro", 70125 Bari, Italy.
Giacomina BrunettiDepartment of Biosciences, Biotechnologies and Environment, University of Bari "A. Moro", 70125 Bari, Italy.ORCID 0000-0002-0681-1432
Patrizia D'EufemiaDepartment of Pediatric, Sapienza University of Rome, 00185 Rome, Italy.
Ospedale Pediatrico Giovanni XXIII · ITSapienza University of Rome · ITUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain-type creatine kinase (CK-BB) increases during osteoclastogenesis, with high circulating amounts in type I osteogenesis imperfecta (OI) following treatment with neridronate, a bisphosphonate able to inhibit osteoclast activity and survival. The aim of this study was to demonstrate the correlation between osteoclastogenesis and CK-BB release from OI patients' osteoclasts treated with different concentrations of neridronate. Our patients showed reduced bone quality, increased levels of CTX I, a marker of bone resorption, and decreased levels of OPG, an inhibitor of osteoclastogenesis. In OI patients, the presence of MCSF and RANKL determined an increased secretion of CK-BB from osteoclasts (

Indexed as

CK-BBneridronateosteoclastogenesisosteogenesis imperfecta

Identifiers

PMID36830994
PMCPMC9953364
OpenAlexW4319298041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.